MCID: PRS004
MIFTS: 31

Prostate Squamous Cell Carcinoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Squamous Cell Carcinoma

Aliases & Descriptions for Prostate Squamous Cell Carcinoma:

Name: Prostate Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Prostate 12 69
Squamous Cell Carcinoma of the Prostate 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10287
NCIt 47 C5536
SNOMED-CT 64 399590005
UMLS 69 C1302530

Summaries for Prostate Squamous Cell Carcinoma

MalaCards based summary : Prostate Squamous Cell Carcinoma, also known as squamous cell carcinoma of prostate, is related to large cell neuroendocrine carcinoma and hypersecretion glaucoma. An important gene associated with Prostate Squamous Cell Carcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Cytoskeletal Signaling and Keratinization. The drugs Fentanyl and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include prostate, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Related Diseases for Prostate Squamous Cell Carcinoma

Diseases related to Prostate Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 large cell neuroendocrine carcinoma 10.3 KLK3 KRT8
2 hypersecretion glaucoma 10.2 KLK3 SMUG1
3 clear cell cystadenofibroma 10.2 KRT5 KRT8
4 parotitis 10.2 KLK3 SMUG1
5 onychodystrophy-anonychia 10.2 KRT5 KRT8
6 uterine disease 10.2 KLK3 SMUG1
7 conventional fibrosarcoma 10.2 CEACAM5 KLK3
8 embryonal testis carcinoma 10.2 KRT5 KRT8
9 vagneur triolle ripert syndrome 10.2 CEACAM5 KLK3
10 vulvar keratoacanthoma-like carcinoma 10.2 CEACAM5 KLK3
11 multidrug-resistant tuberculosis 10.2 KRT5 SMUG1
12 sphenoid sinus squamous cell carcinoma 10.2 CEACAM5 KLK3
13 iris spindle cell melanoma 10.2 CEACAM5 KLK3
14 basaloid squamous cell carcinoma 10.2 CEACAM5 KRT5
15 bladder carcinoma in situ 10.2 CEACAM5 SMUG1
16 pulmonary artery choriocarcinoma 10.2 CEACAM5 SMUG1
17 cranial nerve disease 10.2 CEACAM5 KLK3
18 viral infectious disease 10.2 CEACAM5 SMUG1
19 familial lipoprotein lipase deficiency 10.2 KRT5 SMUG1
20 ocular motility disease 10.2 CEACAM5 SMUG1
21 ovarian wilms' cancer 10.2 CEACAM5 SMUG1
22 vulva adenocarcinoma 10.2 KRT5 KRT8
23 brain stem cancer 10.2 CEACAM5 SMUG1
24 vaginal endometrial stromal sarcoma 10.1 KRT5 SMUG1
25 ulcer of lower limbs 10.1 CEACAM5 SMUG1
26 elephantiasis 10.1 CEACAM5 SMUG1
27 hemangioblastoma 10.1 B2M SMUG1
28 hypertropia 10.1 CEACAM5 SMUG1
29 scirrhous adenocarcinoma 10.1 KRT5 KRT8
30 bulbar polio 10.1 CEACAM5 SMUG1
31 venezuelan equine encephalitis 10.1 B2M SMUG1
32 steroid-induced glaucoma - borderline 10.1 KLK3 KRT7
33 proteus-like syndrome 10.1 KRT7 KRT8
34 bubonic plague 10.1 B2M HLA-A
35 envenomization by bothrops lanceolatus 10.1 KRT7 KRT8
36 medullomyoblastoma 10.1 KLK3 KRT7
37 suppurative lymphadenitis 10.1 KRT5 KRT7
38 skin amelanotic melanoma 10.1 KRT5 KRT7
39 fuchs' heterochromic uveitis 10.1 KLK3 KRT7
40 ebola hemorrhagic fever 10.1 KRT5 KRT7
41 vulvar alveolar soft part sarcoma 10.1 CEACAM5 KRT5 KRT8
42 sarcomatoid mesothelioma 10.0 KRT7 KRT8
43 bone leiomyosarcoma 10.0 KRT7 SMUG1
44 sensory organ benign neoplasm 10.0 KRT7 KRT8
45 mucosal melanoma 10.0 KRT7 SMUG1
46 rectum lymphoma 10.0 KRT7 KRT8
47 bilateral hypoactive labyrinth 10.0 KRT5 KRT7
48 bardet-biedl syndrome 10.0 CEACAM5 KLK3 SMUG1
49 deep angioma 10.0 CEACAM5 KRT7
50 lung combined type small cell carcinoma 10.0 KRT5 KRT7

Graphical network of the top 20 diseases related to Prostate Squamous Cell Carcinoma:



Diseases related to Prostate Squamous Cell Carcinoma

Symptoms & Phenotypes for Prostate Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.77 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.77 KRT5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.77 KRT8 KRT5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.77 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.77 KRT8
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 KRT7
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.77 KRT8 KRT5 KRT7
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.77 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.77 KRT5 KRT7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.55 HLA-A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.55 HLA-A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.55 HLA-A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.55 KRT8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.55 KRT7 KRT8
15 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.55 HLA-A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.55 HLA-A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.55 HLA-A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.55 KRT7 KRT8
19 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.55 HLA-A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.55 KRT8
21 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.55 HLA-A
22 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.55 HLA-A KRT7 KRT8

Drugs & Therapeutics for Prostate Squamous Cell Carcinoma

Drugs for Prostate Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
3 Liver Extracts Phase 3,Phase 2,Phase 1
4 Adjuvants, Anesthesia Phase 3
5 Analgesics Phase 3
6 Analgesics, Opioid Phase 3
7 Anesthetics Phase 3
8 Anesthetics, General Phase 3
9 Anesthetics, Intravenous Phase 3
10 Central Nervous System Depressants Phase 3
11 Narcotics Phase 3
12 pancreatic polypeptide Phase 3
13 Peripheral Nervous System Agents Phase 3
14 Antimitotic Agents Phase 3,Phase 1
15 Cola Nutraceutical Phase 3,Phase 2,Phase 1
16
Indinavir Approved Phase 2 150378-17-9 5362440
17
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
18
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
19
Everolimus Approved Phase 2 159351-69-6 6442177
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
22 Anti-HIV Agents Phase 2
23 Anti-Infective Agents Phase 2,Phase 1
24 Anti-Retroviral Agents Phase 2
25 Antiviral Agents Phase 2,Phase 1
26 Cytochrome P-450 CYP3A Inhibitors Phase 2
27 Cytochrome P-450 Enzyme Inhibitors Phase 2,Phase 1
28 HIV Protease Inhibitors Phase 2
29
protease inhibitors Phase 2
30 Immunosuppressive Agents Phase 2,Phase 1
31 Gastrointestinal Agents Phase 1, Phase 2
32 Androgens Phase 1, Phase 2
33 Antibodies Phase 1, Phase 2
34 Immunoglobulins Phase 1, Phase 2
35 Antibodies, Monoclonal Phase 1, Phase 2
36 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
37 topoisomerase I inhibitors Phase 1, Phase 2
38 Topoisomerase Inhibitors Phase 1, Phase 2
39 Thromboplastin Phase 1, Phase 2
40 Anti-Bacterial Agents Phase 2
41 Antibiotics, Antitubercular Phase 2
42 Antifungal Agents Phase 2
43 Carboxymethylcellulose Sodium Phase 1, Phase 2
44 Cathartics Phase 1, Phase 2
45 Interferon Inducers Phase 1, Phase 2
46 interferons Phase 1, Phase 2
47 Laxatives Phase 1, Phase 2
48 Poly I-C Phase 1, Phase 2
49 Poly ICLC Phase 1, Phase 2
50
tremelimumab Phase 1, Phase 2

Interventional clinical trials:

(show all 50)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
3 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
4 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck Completed NCT01059643 Phase 2
5 Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT00605618 Phase 1, Phase 2
6 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
7 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Recruiting NCT02001623 Phase 1, Phase 2
8 Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Recruiting NCT02646319 Phase 2
9 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2
10 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
11 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2
12 A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer Terminated NCT02042885 Phase 1, Phase 2
13 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
14 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
15 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
16 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1
17 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1
18 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
19 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
20 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
21 Spectroscopy With Surface Coils and Decoupling Completed NCT00581815 Phase 1
22 A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas Completed NCT01588678 Phase 1
23 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
24 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
25 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Recruiting NCT01772004 Phase 1
26 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Recruiting NCT03098160 Phase 1
27 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting NCT03076372 Phase 1
28 Safety Study of MGA271 in Refractory Cancer Recruiting NCT01391143 Phase 1
29 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting NCT02628535 Phase 1
30 A Phase 1 Trial of SRA737 in Subjects With Advanced Cancer Recruiting NCT02797964 Phase 1
31 AZD8186 First Time In Patient Ascending Dose Study Recruiting NCT01884285 Phase 1
32 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Active, not recruiting NCT01353625 Phase 1
33 Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer Suspended NCT00909558 Phase 1
34 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1
35 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1
36 Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Withdrawn NCT02567396 Phase 1
37 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733
38 Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
39 A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer Completed NCT01614002
40 The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer Completed NCT00605488
41 Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer Completed NCT00364715
42 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
43 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
44 Questionnaire in Screening Older Patients With Cancer Completed NCT00963911
45 Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Completed NCT00002520
46 Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma Recruiting NCT02119559
47 Autologous Natural Killer T Cells Infusion for the Treatment of Cancer Recruiting NCT01801852
48 A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers Active, not recruiting NCT00122239
49 FACBC for Head and Neck Cancers Suspended NCT01933269 Early Phase 1
50 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors Withdrawn NCT00499291

Search NIH Clinical Center for Prostate Squamous Cell Carcinoma

Genetic Tests for Prostate Squamous Cell Carcinoma

Anatomical Context for Prostate Squamous Cell Carcinoma

MalaCards organs/tissues related to Prostate Squamous Cell Carcinoma:

39
Prostate

Publications for Prostate Squamous Cell Carcinoma

Variations for Prostate Squamous Cell Carcinoma

Expression for Prostate Squamous Cell Carcinoma

Search GEO for disease gene expression data for Prostate Squamous Cell Carcinoma.

Pathways for Prostate Squamous Cell Carcinoma

Pathways related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.92 KRT5 KRT7 KRT8
2
Show member pathways
11.79 KRT5 KRT7 KRT8
3
Show member pathways
11.11 B2M HLA-A
4
Show member pathways
10.83 KRT5 KRT7 KRT8
5 10.35 B2M HLA-A

GO Terms for Prostate Squamous Cell Carcinoma

Cellular components related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.43 KRT5 KRT7 KRT8
2 recycling endosome membrane GO:0055038 9.37 B2M HLA-A
3 ER to Golgi transport vesicle membrane GO:0012507 9.32 B2M HLA-A
4 extracellular exosome GO:0070062 9.17 B2M CEACAM5 HLA-A KLK3 KRT5 KRT7
5 MHC class I protein complex GO:0042612 9.16 B2M HLA-A
6 keratin filament GO:0045095 9.13 KRT5 KRT7 KRT8

Biological processes related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.33 KRT5 KRT7 KRT8
2 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.26 B2M HLA-A
3 cornification GO:0070268 9.13 KRT5 KRT7 KRT8
4 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 8.62 B2M HLA-A

Molecular functions related to Prostate Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 scaffold protein binding GO:0097110 8.62 KRT5 KRT8

Sources for Prostate Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....